Drugs used in tuberculosis and leprosy

Global tuberculosis control: a short update to the 2009 report. WHO/HTM/TB/2009.426. http://www.who.int/tb/publications/global_report/2009/update/en/index.html Medical Research Council, 1948, Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation, Br Med J, 4582, 769 Mitchison, 2005, The diagnosis and therapy of tuberculosis during the past 100 years, Am J Respir Crit Care Med, 171, 699, 10.1164/rccm.200411-1603OE Frieden, 1993, The emergence of drug resistant tuberculosis in New York City, N Engl J Med, 328, 512, 10.1056/NEJM199302253280801 Gandhi, 2006, Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa, Lancet, 368, 1575, 10.1016/S0140-6736(06)69573-1 World Health Organization, 2010, Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO global report Scarparo, 2004, Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampicin and ethambutol and comparison with the BACTEC 460TB method, J Clin Microbiol, 42, 1109, 10.1128/JCM.42.3.1109-1114.2004 Piersimoni, 2006, Current perspective on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems, J Clin Microbiol, 44, 20, 10.1128/JCM.44.1.20-28.2006 Ejigu, 2008, Microscopic observation drug susceptibility assay provides rapid and reliable identification of MDR-TB, Int J Tuberc Lung Dis, 12, 332 Palomino, 2007, Rapid drug resistance detection in Mycobacterium tuberculosis. A review of calorimetric methods, Clin Microbiol Infect, 13, 754, 10.1111/j.1469-0691.2007.01698.x Banaiee, 2008, Evaluation of a semiautomated reporter phage assay for susceptibility testing of Mycobacterium tuberculosis isolates in South Africa, Tuberculosis, 88, 64, 10.1016/j.tube.2007.08.006 Hillmann, 2007, Evaluation of Genotype MTBDR Plus assay for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens, J Clin Microbiol, 45, 2635, 10.1128/JCM.00521-07 Telenti, 1993, Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis, Lancet, 341, 647, 10.1016/0140-6736(93)90417-F Johnson, 2006, Drug resistance in Mycobacterium tuberculosis, Curr Issues Mol Biol, 8, 97 Ahmad, 2004, Contribution of AGC to ACC and other mutations at Codon 315 of the kat G gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East, Int J Antimicrob Agents, 23, 473, 10.1016/j.ijantimicag.2003.10.004 Ahmad, 2007, Frequency of embB codon 306 mutations in ethambutol susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait, Tuberculosis, 87, 123, 10.1016/j.tube.2006.05.004 Ahmad, 2009, Recent advances in the diagnosis and treatment of multi-drug resistant tuberculosis, Respir Med, 103, 1777, 10.1016/j.rmed.2009.07.010 Viveiros, 2005, J Clin Microbiol, 43, 4880, 10.1128/JCM.43.9.4880-4884.2005 Evans, 2009, Rapid genotypic assays to identify drug resistant Mycobacterium tuberculosis in South Africa, J Antimicrob Chemother, 63, 11, 10.1093/jac/dkn433 Sekiguchi, 2007, Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains, J Clin Microbiol, 45, 2802, 10.1128/JCM.00352-07 Giannoni, 2005, Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis, Antimicrob Agents Chemother, 49, 2928, 10.1128/AAC.49.7.2928-2933.2005 Suchindran, 2009, Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review, PLoS One, 4, 1, 10.1371/journal.pone.0005561 Rich, 2006, Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB, Int J Tuberc Lung Dis, 10, 290 Riekstina, 2007, Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia, Int J Tuberc Lung Dis, 11, 585 Nathanson, 2006, Multidrug-resistant tuberculosis management in resource-limited settings, Emerg Infect Dis, 12, 1389, 10.3201/eid1209.051618 Andries, 2005, A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis, Science, 307, 223, 10.1126/science.1106753 Nuermberger, 2008, Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis, Antimicrob Agents Chemother, 52, 1522, 10.1128/AAC.00074-08 Matsumoto, 2006, OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice, PLoS Med, 3, e466, 10.1371/journal.pmed.0030466 Protopopova, 2005, Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines, J Antimicrob Chemother, 56, 968, 10.1093/jac/dki319 Makhlouf, 2008, A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases, Hepatol Int, 2, 353, 10.1007/s12072-008-9085-y Zabana, 2008, Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy, Inflamm Bowel Dis, 14, 1387, 10.1002/ibd.20496 Marks, 2009, Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs, Int J STD AIDS, 20, 339, 10.1258/ijsa.2008.008361 Chen, 2008, Tuberculosis in southern Chinese renal-transplant recipients, Clin Transplant, 22, 780, 10.1111/j.1399-0012.2008.00878.x Guida, 2009, Tuberculosis in renal transplant recipients: a Brazilian center registry, Transplant Proc, 41, 883, 10.1016/j.transproceed.2009.01.075 Chou, 2008, Tuberculosis after heart transplantation: twenty years of experience in a single center in Taiwan, Transplant Proc, 40, 2631, 10.1016/j.transproceed.2008.08.013 Holty, 2009, Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data, Liver Transpl, 15, 894, 10.1002/lt.21709 Clemente, 2009, Tuberculosis in liver transplant recipients: a single Brazilian center experience, Transplantation, 87, 397, 10.1097/TP.0b013e31819289d0 Toibaro, 2008, Pharmacokinetics interaction studies between rifampicin and protease inhibitors: methodological problems, AIDS, 22, 2046, 10.1097/QAD.0b013e3283112bb7 Matteelli, 2009, Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis, J Acquir Immune Defic Syndr, 52, 64, 10.1097/QAI.0b013e3181b0328f Manosuthi, 2009, A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study, Clin Infect Dis, 48, 1752, 10.1086/599114 Suzuki, 2008, Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs, Chest, 134, 1027, 10.1378/chest.07-3088 Kwon, 2008, Cycloserine-induced encephalopathy: evidence on brain MRI, Eur J Neurol, 15, e60, 10.1111/j.1468-1331.2008.02171.x Vancine-Califani, 2008, Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura, Platelets, 19, 489, 10.1080/09537100802315110 Zhu, 2009, Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome, J Clin Pharm Ther, 34, 480, 10.1111/j.1365-2710.2008.00991.x Ranawaka, 2008, Dapsone-induced haemolytic anaemia, hepatitis and agranulocytosis in a leprosy patient with normal glucose-6-phosphate-dehydrogenase activity, Lepr Rev, 79, 436, 10.47276/lr.79.4.436 Satarasinghe, 2009, Total agranulocytosis caused by dapsone therapy for tuberculoid leprosy—an unappreciated serious side effect of anti-leprosy treatment with clinical implications, Drug Metabol Drug Interact, 24, 325 Lambert, 1982, Delayed sulfhemoglobinemia after acute dapsone intoxication, J Toxicol Clin Toxicol, 19, 45, 10.3109/15563658208990365 Hansen, 1994, Dapsone intoxication: two case reports, J Emerg Med, 12, 347, 10.1016/0736-4679(94)90277-1 Goulart, 2005, Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy, Lepr Rev, 76, 167 Borrás-Blasco, 2005, Pure red cell aplasia associated with dapsone therapy, Ann Pharmacother, 39, 1137, 10.1345/aph.1E349 Gill, 1995, N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity, Br J Clin Pharmacol, 40, 531, 10.1111/j.1365-2125.1995.tb05797.x Coleman, 2001, Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention, Toxicology, 162, 53, 10.1016/S0300-483X(01)00360-2 Besser, 2009, Preservation of basophils in dapsone-induced agranulocytosis suggests a possible pathogenetic role for leukocyte peroxidases, Int J Lab Hematol, 31, 245, 10.1111/j.1751-553X.2007.00983.x Williams, 2005, Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for Pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels, Pediatr Blood Cancer, 44, 55, 10.1002/pbc.20164 Naik, 2008, Dapsone-induced hemolytic anemia in lung allograft recipients, J Heart Lung Transplant, 27, 1198, 10.1016/j.healun.2008.07.025 Stotland, 2009, Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris, Am J Clin Dermatol, 10, 221, 10.2165/00128071-200910040-00002 Piette, 2008, Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris, Arch Dermatol, 144, 1564, 10.1001/archdermatol.2008.518 Goolamali, 2009, The use of cimetidine to reduce dapsone-dependent haematological side-effects in a patient with mucous membrane pemphigoid, Clin Exp Dermatol, 34, e1025, 10.1111/j.1365-2230.2009.03710.x Flosadóttir, 2008, Full dapsone dose made possible by control of anaemia with darbepoetin-alpha, Acta Derm Venereol, 88, 540, 10.2340/00015555-0502 Thunga, 2008, Effectiveness of hemodialysis in acute dapsone overdose—a case report, Am J Emerg Med, 26, 1070, 10.1016/j.ajem.2008.03.031 Kar, 2008, Dapsone-induced photosensitivity: a rare clinical presentation, Photodermatol Photoimmunol Photomed, 24, 270, 10.1111/j.1600-0781.2008.00372.x Chun, 2009, Dapsone hypersensitivity syndrome with circulating 190-kDa and 230-kDa autoantibodies, Clin Exp Dermatol, 34, e798, 10.1111/j.1365-2230.2009.03527.x Sheen, 2009, Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan, J Dermatolog Treat, 20, 340, 10.3109/09546630802691317 Chawla, 2009, Ethambutol chiasmal toxicity with bitemporal hemianopia, Semin Ophthalmol, 24, 221, 10.1080/08820530903185640 Lee, 2008, Incidence and clinical features of ethambutol-induced optic neuropathy in Korea, J Neuroophthalmol, 28, 269, 10.1097/WNO.0b013e31818e3c6b Liu, 2008, Multifocal electroretinographic abnormalities in ethambutol-induced visual loss, J Neuroophthalmol, 28, 278, 10.1097/WNO.0b013e31818e3ece Menon, 2009, Prospective evaluation of visual function for early detection of ethambutol toxicity, Br J Ophthalmol, 93, 1251, 10.1136/bjo.2008.148502 Ziakas, 2009, 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity, Clin Infect Dis, 49, 1883, 10.1086/647944 Hawkes, 2008, Neuroimaging findings in isoniazid central nervous system toxicity, presumed intramyelinic edema, Eur J Paediatr Neurol, 12, 512, 10.1016/j.ejpn.2007.12.002 Semfke, 2009, Histologically proven isoniazid hepatotoxicity in complicated tuberculous salpingitis, Ther Adv Respir Dis, 3, 159, 10.1177/1753465809345500 Angelini, 2009, Increase in plasma levels of clozapine after addition of isoniazid, J Clin Psychopharmacol, 29, 190, 10.1097/JCP.0b013e31819a6b53 Stover, 2000, A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis, Nature, 405, 962, 10.1038/35016103 Tyagi, 2005, Bactericidal activity of the nitroimidazopyran PA-824 in the murine model of tuberculosis, Antimicrob Agents Chemother, 49, 2289, 10.1128/AAC.49.6.2289-2293.2005 Ginsberg, 2009, Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects, Antimicrob Agents Chemother, 53, 3726, 10.1128/AAC.00112-09 El Aïdli, 2009, Recurrent dysosmia induced by pyrazinamide, Fundam Clin Pharmacol, 23, 539, 10.1111/j.1472-8206.2009.00736.x Papastavros, 2002, Adverse events associated with Pyrazinamide and levofloxacin in the treatment of latent multi-drug resistant tuberculosis, CMAJ, 167, 131 McIlleron, 2007, Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers, J Antimicrob Chemother, 60, 1398, 10.1093/jac/dkm393 Chen, 2009, Acute generalized exanthematous pustulosis caused by rifabutin, Arch Dermatol, 145, 1069, 10.1001/archdermatol.2009.221 Boulanger, 2009, Pharmacokinetic evaluation of rifabutin in combination with lopinavir–ritonavir in patients with HIV infection and active tuberculosis, Clin Infect Dis, 49, 1305, 10.1086/606056 Nguyen, 2009, Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections, Clin Microbiol Infect, 15, 1163, 10.1111/j.1469-0691.2009.02761.x Riedel, 2008, Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus, Antimicrob Agents Chemother, 52, 2463, 10.1128/AAC.00300-08 Neunert, 2008, Intravascular hemolysis following low dose daily rifampin, Pediatr Blood Cancer, 51, 821, 10.1002/pbc.21709 Haas, 2009, Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir, J Acquir Immune Defic Syndr, 50, 290, 10.1097/QAI.0b013e318189a7df He, 2009, Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism, Clin Chim Acta, 405, 49, 10.1016/j.cca.2009.04.003 L'homme, 2009, Clinical experience with the combined use of lopinavir/ritonavir and rifampicin, AIDS, 23, 863, 10.1097/QAD.0b013e328329148e Nieminen, 2009, Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone, Anesthesiology, 110, 1371, 10.1097/ALN.0b013e31819faa54 Schmitt, 2009, Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers, Arch Drug Info, 2, 8, 10.1111/j.1753-5174.2009.00017.x Nassr, 2009, Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects, Br J Clin Pharmacol, 68, 580, 10.1111/j.1365-2125.2009.03478.x Antonicelli, 2009, IgE-mediated reactions to rifaximin and rifamycin SV and cross-reactivity among rifamycins, Allergy, 64, 1232, 10.1111/j.1398-9995.2009.02034.x